Developing Non-Ototoxic Aminoglycosides

开发非耳毒性氨基糖苷类药物

基本信息

  • 批准号:
    8336858
  • 负责人:
  • 金额:
    $ 23.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-09-21 至 2014-08-31
  • 项目状态:
    已结题

项目摘要

Abstract: Aminoglycoside (AGs) antibiotics are used worldwide because of their potent antimicrobial activities and low cost. They are widely used despite the significant side effects of ototoxicity and nephrotoxicity. Recent evidence from independent laboratories demonstrated that AGs accumulate rapidly in hair cells because of their ability to enter these cells through the mechanoelectric transducer channel located near the tops of the stereocilia. Channel biophysical properties promote entry through the channel but limit exit through these same channels. Our data clearly show that ototoxicity can be prevented by blocking entry via these channels. The goal of this proposal is to develop novel non-ototoxic aminoglycosides. Our team has unique insights into the biophysical properties of the mechanically gated channels and can use this knowledge to design compounds that are sterically and/or electrically restricted from entering the channel and therefore the hair cell. Sites for modification are selected on the AG backbone so as not to interfere with antimicrobial activity. We have in hand the ability to investigate these compounds at the channel, cellular, end organ, system and whole animal level, using electrophysiological, optical, molecular and pharmacological means to monitor ototoxicity as well as antimicrobial activity. Complementary to the development of these compounds will be identifying the mechanism of entry of the AGs into the endolymph compartment. Upon identification of this pathway we will devise means to limit transport of existing AGs so that a co-treatment plan might prevent access of the AGs to the MET channel and thus limit entry into hair cells. The focus of this proposal is to design treatment regimes, either by creating novel AGs, or co-treatment plans, that will ameliorate ototoxicity due to AG administration. At the end of the proposed two-year research period, we will have applied our unique knowledge base and skill sets to gain insights into the effectiveness of either of these approaches in reducing ototoxicity caused AGs.
摘要: 氨基糖苷类(AG)抗生素由于其强效的抗肿瘤活性而在世界范围内被广泛使用。 抗菌活性和低成本。它们被广泛使用,尽管重要的一面 耳毒性和肾毒性效应。来自独立实验室的最新证据 表明AG在毛细胞中迅速积累,因为它们能够进入毛细胞, 这些细胞通过位于膜顶部附近的机电换能器通道, 静纤毛通道生物物理特性促进通过通道进入,但限制 通过同样的渠道退出。我们的数据清楚地表明,耳毒性可能是 通过阻止这些通道的进入来阻止。该提案的目标是发展 新的非耳毒性氨基糖苷类。我们的团队对生物物理学有着独特的见解, 机械门控通道的特性,并可以使用这些知识来设计 在空间上和/或电学上被限制进入通道的化合物 也就是毛细胞在AG骨架上选择修饰位点, 不干扰抗菌活性。我们有能力调查 这些化合物在通道、细胞、终末器官、系统和整个动物水平, 使用电生理学、光学、分子和药理学手段来监测 耳毒性以及抗微生物活性。与这些发展相辅相成 化合物将鉴定AG进入内淋巴的机制 车厢一旦识别出这条途径,我们将设计出限制运输的方法 现有的AG,以便共同治疗计划可能会阻止AG访问MET 通道,从而限制进入毛细胞。本提案的重点是设计 治疗方案,无论是通过创建新的AG,或共同治疗计划,这将 改善AG给药引起的耳毒性。在拟议的两年期结束时, 在研究期间,我们将运用我们独特的知识基础和技能, 深入了解这些方法在降低耳毒性方面的有效性 导致AG。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Anthony J Ricci其他文献

Uncoordinated maturation of developing and regenerating postnatal mammalian vestibular hair cells
产后哺乳动物前庭毛细胞发育和再生的不协调成熟
  • DOI:
    10.1371/journal.pbio.3000326
  • 发表时间:
    2019-07
  • 期刊:
  • 影响因子:
    9.8
  • 作者:
    Tian Wang;Mamiko Niwa;Zahra N Sayyid;Davood K Hosseini;Nicole Pham;Sherri M Jones;Anthony J Ricci;Alan G Cheng
  • 通讯作者:
    Alan G Cheng

Anthony J Ricci的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Anthony J Ricci', 18)}}的其他基金

Abberior Infinity Line Upright 3D STED/Confocal Microscope
Abberior Infinity Line 正置 3D STED/共焦显微镜
  • 批准号:
    10632948
  • 财政年份:
    2023
  • 资助金额:
    $ 23.95万
  • 项目类别:
Probing how hair bundle mechanical properties shape the mechanotransducer receptor current
探讨发束机械特性如何塑造机械传感器受体电流
  • 批准号:
    10778103
  • 财政年份:
    2023
  • 资助金额:
    $ 23.95万
  • 项目类别:
Identifying new sensors for in vivo cochlear imaging
识别用于体内耳蜗成像的新传感器
  • 批准号:
    10433182
  • 财政年份:
    2022
  • 资助金额:
    $ 23.95万
  • 项目类别:
Identifying new sensors for in vivo cochlear imaging
识别用于体内耳蜗成像的新传感器
  • 批准号:
    10617806
  • 财政年份:
    2022
  • 资助金额:
    $ 23.95万
  • 项目类别:
Functional Integrity of the Aging Auditory Synapse
衰老听觉突触的功能完整性
  • 批准号:
    9151173
  • 财政年份:
    2016
  • 资助金额:
    $ 23.95万
  • 项目类别:
Developing Non-Ototoxic Aminoglycosides
开发非耳毒性氨基糖苷类药物
  • 批准号:
    8225109
  • 财政年份:
    2011
  • 资助金额:
    $ 23.95万
  • 项目类别:
2-photon imaging system
2光子成像系统
  • 批准号:
    7792526
  • 财政年份:
    2010
  • 资助金额:
    $ 23.95万
  • 项目类别:
Calcium Regulation of Mechanotransduction
机械传导的钙调节
  • 批准号:
    7850399
  • 财政年份:
    2009
  • 资助金额:
    $ 23.95万
  • 项目类别:
Synaptic specialization of auditory hair cells
听觉毛细胞的突触特化
  • 批准号:
    7992365
  • 财政年份:
    2008
  • 资助金额:
    $ 23.95万
  • 项目类别:
Synaptic specialization of auditory hair cells
听觉毛细胞的突触特化
  • 批准号:
    7600679
  • 财政年份:
    2008
  • 资助金额:
    $ 23.95万
  • 项目类别:

相似海外基金

Disrupting Dogma: Investigating LPS Biosynthesis Inhibition as an Alternative Mechanism of Action of Aminoglycoside Antibiotics
颠覆教条:研究 LPS 生物合成抑制作为氨基糖苷类抗生素的替代作用机制
  • 批准号:
    10653587
  • 财政年份:
    2023
  • 资助金额:
    $ 23.95万
  • 项目类别:
Shaping Next Generation Aminoglycoside Antibiotics for Treatment of Multidrug-Resistant Diseases
打造下一代氨基糖苷类抗生素治疗多重耐药性疾病
  • 批准号:
    10585038
  • 财政年份:
    2023
  • 资助金额:
    $ 23.95万
  • 项目类别:
Creation of Next-generation Aminoglycoside Antibiotics Active against Multidrug-resistant Gram-negative Bacteria
开发对多重耐药革兰氏阴性菌具有活性的下一代氨基糖苷类抗生素
  • 批准号:
    20K06982
  • 财政年份:
    2020
  • 资助金额:
    $ 23.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Shaping Next Generation Aminoglycoside Antibiotics for Treatment of Multidrug- Resistant Diseases
打造下一代氨基糖苷类抗生素治疗多重耐药性疾病
  • 批准号:
    9934590
  • 财政年份:
    2019
  • 资助金额:
    $ 23.95万
  • 项目类别:
Combating Antibiotic Resistance to Aminoglycoside Antibiotics through Chemical Synthesis
通过化学合成对抗氨基糖苷类抗生素的耐药性
  • 批准号:
    392481159
  • 财政年份:
    2017
  • 资助金额:
    $ 23.95万
  • 项目类别:
    Research Fellowships
Shaping Next Generation Aminoglycoside Antibiotics for Treatment of Multidrug-Resistant Diseases
打造下一代氨基糖苷类抗生素治疗多重耐药性疾病
  • 批准号:
    9082038
  • 财政年份:
    2016
  • 资助金额:
    $ 23.95万
  • 项目类别:
Functional analysis of radical SAM enzymes involved in the biosynthesis of aminoglycoside antibiotics
氨基糖苷类抗生素生物合成中自由基SAM酶的功能分析
  • 批准号:
    26410174
  • 财政年份:
    2014
  • 资助金额:
    $ 23.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
EAPSI:Synthesis of Aminoglycoside Antibiotics
EAPSI:氨基糖苷类抗生素的合成
  • 批准号:
    1106886
  • 财政年份:
    2011
  • 资助金额:
    $ 23.95万
  • 项目类别:
    Fellowship Award
Preclinical evaluation of aminoglycoside antibiotics-derived amphiphiles (AADAs)
氨基糖苷类抗生素衍生的两亲物 (AADA) 的临床前评估
  • 批准号:
    185482
  • 财政年份:
    2009
  • 资助金额:
    $ 23.95万
  • 项目类别:
    Operating Grants
AMINOGLYCOSIDE ANTIBIOTICS FOR CYSTIC FIBROSIS
治疗囊性纤维化的氨基糖苷类抗生素
  • 批准号:
    6565399
  • 财政年份:
    2001
  • 资助金额:
    $ 23.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了